CHKT.OB .54--
B: Juravinski Cancer Centre Investigator to Present Phase I/II Data at the Molec
lar Targets and Cancer Therapeutics International Conference on Chemokine's Lead
Drug Candidate, CTCE-9908 ( Market Wire )
VANCOUVER, BRITISH COLUMBIA, Sep 19, 2007 (MARKET WIRE via COMTEX) --
Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB:
CHKT), a biotechnology company developing chemokine-based therapies
to treat cancer, blood disorders, and vascular diseases, announced
that an abstract, entitled "Phase I/II study of CTCE-9908, a novel
anticancer agent that inhibits CXCR4, in patients with advanced solid
cancers", submitted by the Investigators has been accepted by the
American Association for Cancer Research ("AACR") for presentation at
the Molecular Targets and Cancer Therapeutics International
Conference being held in San Francisco, California on October 22-26,
2007. The abstract will be presented by Dr. Sebastien Hotte,
Assistant Professor, Department of Oncology, McMaster University and
Medical Oncologist and Head, Phase I Programme, Juravinski Cancer
Centre.
Investigators at the Juravinski Cancer Centre and the Lady Davis
Jewish General Hospital have been studying the safety and early
efficacy of CTCE-9908, lead drug candidate from Chemokine
Therapeutics, with late stage cancer patients as part of a Phase I/II
study. An international multi-centre Phase II study is planned for
year end.
About CTCE-9908
CTCE-9908 is a peptide analog of the chemokine SDF-1, and an
antagonist of its receptor, CXCR4. SDF-1 is the only known naturally
occurring chemokine that binds to CXCR4, which is present on many
cancer cells. This binding process is believed to be critical in the
metastasis (or spread) of cancer cells to distant locations in the
body, where they form secondary tumors. Approximately 90% of cancer
deaths are due to metastasis. We believe that CTCE-9908 interferes
with the metastatic process of many cell types.
About American Association for Cancer Research
AACR is one of the oldest and largest scientific organization in the
world focused on every aspect of high-quality, innovative cancer
research. Its reputation for scientific breadth and excellence
attract the premier researchers in the field. The programs and
services of AACR foster the exchange of knowledge and new ideas among
scientists dedicated to cancer research, provide training
opportunities for the next generation of cancer researchers, and
increase public understanding of cancer.
About Chemokine Therapeutics Corp. (TSX: CTI)(OTCBB: CHKT)
Chemokine Therapeutics is a product-focused biotechnology company
developing drugs in the field of chemokines. Chemokines are a class
of signaling proteins which play a critical role in the growth,
differentiation, and maturation of cells necessary for fighting
infection as well as tissue repair and regeneration. Chemokines also
have an important role in cancer metastasis and growth. Chemokine
Therapeutics is a leader in research in the field of chemokines and
has several products in various stages of development.
Safe Harbor Statement under the U. S. Private Securities Litigation
Reform Act of 1995: Statements in this document regarding
managements' future expectations, beliefs, goals, plans or prospects
constitute forward-looking statements that involve risks and
uncertainties, which may cause actual results to differ materially
from the statements made. For this purpose, any statements that are
contained herein that are not statements of historical fact may be
deemed to be forward-looking statements. Without limiting the
foregoing, the words "believes", "anticipates", "plans", "intends",
"will", "should", "expects", "projects", and similar expressions are
intended to identify forward-looking statements. You are cautioned
that such statements are subject to a multitude of risks and
uncertainties that could cause actual results, future circumstances,
or events to differ materially from those projected in the
forward-looking statements. These risks include, but are not limited
to, those associated with the success of research and development
programs, the regulatory approval process, competition, securing and
maintaining corporate alliances, market acceptance of the Company's
products, the availability of government and insurance reimbursements
for the Company's products, the strength of intellectual property,
financing capability, the potential dilutive effects of any
financing, reliance on subcontractors and key personnel and other
risks detailed from time-to-time in the Company's public disclosure
documents and other filings with the U.S. Securities and Exchange
Commission and Canadian securities regulatory authorities.
Forward-looking statements are made as of the date hereof, and the
Company disclaims any intention and has no obligation or
responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
Contacts:
Chemokine Therapeutics Corp.
Mr. Don Evans
Director of Public Relations
(604) 822-0305 or 1-888-822-0305
(604) 822-0302 (FAX)
Email: devans@chemokine.net
Website: www.chemokine.net
SOURCE: Chemokine Therapeutics Corp.
mailto:devans@chemokine.net
chemokine.net
Copyright 2007 Market Wire, All rights reserved.
*** end of story *** |
